ClinicalTrials.gg
Not yet recruitingNCT07932080EMAILUpdated Nov 12, 2026

Evaluation of the Predictive Value of Microemboli Detected by Robotic Transcranial Doppler for the Occurrence of an Acute Ischemic Stroke or Left Ventricular Thrombus in STEMI Patients With Left Ventricular Dysfunction

An interventional study of Transcranial doppler (TCD) in STEMI, Left Ventricular Thrombus and Acute Ischemic Stroke, sponsored by CHC Montlegia. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by CHC Montlegia · Not applicable, Interventional, and Diagnostic

Updated Nov 12, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to define a correlation between the number of microembolic signals (MES) detected and the risk of occurrence of an Acute Ischemic Stroke (AIS) at 2 years or a Left Ventricular Thrombus (LVT) at 6 weeks Participants will perform a transcranial doppler with MES detection.

02

Conditions studied

  • STEMI
  • Left Ventricular Thrombus
  • Acute Ischemic Stroke
03

In context

ST Elevation Myocardial Infarction

850 studies on the registry are indexed under ST Elevation Myocardial Infarction; 197 are open to participants now.

This study's planned enrollment of 116 is below the median of 194 across 527 interventional studies indexed under ST Elevation Myocardial Infarction.

Browse ST Elevation Myocardial Infarction studies →

Lead sponsor

CHC Montlegia is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged 18 or over
  • Patient with proven post-STEMI LVD within 72 hours of hospitalization for acute STEMI
  • less than 35%
  • Express consent to participate in the study
  • Member or beneficiary of a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Patient with known carotid stenosis greater than 50%.
  • Patient with a history of AIS
  • Patient with AF
  • Patient with mechanical valve
  • Patient benefiting from a legal protection measure
  • Pregnant or breast-feeding women
  • History of cardiorespiratory arrest
  • of \<6 months

Secondary exclusion criteria

  • Withdrawal of consent to participate in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    1

    Device: Transcranial doppler (TCD)

Interventions

  • DeviceTranscranial doppler (TCD)

    A TCD with MES detection will be performed the day of the inclusion. Another TCD will be performed at 6 weeks of the inclusion. They will then receive telephone follow-up at one year, followed by a final visit two years after inclusion, blinded to the results of the TCD.

06

What researchers measure

Primary outcomes

  1. Demonstration of a correlation between the number of MES detected and the 2-year risk of AIS or the occurrence of a LVT at 6 weeks in patients with post-STEMI LVD.

    Time frame: To the enrollment period to 2-years of AIS or 6-weeks of a LVT

Secondary outcomes

  1. Demonstration of a correlation between the number of MES detected and the treatment given (single anti-aggregation, double anti-aggregation, anti-coagulation) in patients suffering from LVD

    Time frame: To the enrollment period to 2-years of AIS or 6-weeks of a LVT

  2. Demonstration of a correlation between the variation in the number of MES detected and the modification of the treatment administered (single anti-aggregation, double anti-aggregation, anti-coagulation) in patients suffering from LVD

    Time frame: To the enrollment period to 2-years of AIS or 6-weeks of a LVT

  3. Demonstration of a correlation between the number of MES and the LVD rate according to the ACCF/AHA Heart Failure classification

    Time frame: At screening

  4. Demonstration of a correlation between the number of MES detected and the risk of occurrence of an AIS at 2 years or LVT at 6 weeks in patients suffering from LVD, classified by subgroup of cardiac decompensation according to the ACCF/AHA Heart Failur

    Time frame: To the enrollment period to 2-years of AIS or 6-weeks of a LVT

  5. Creation of a large multicentric prospective follow-up database of patients suffering from LVD, whether symptomatic or not

    Time frame: To the enrollment period to the end of the follow-up, three years after

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 134 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 12 months is below that.

Counting every sponsor, half of 143 studies reached it within 38 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 12, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07932080
Lead sponsor
CHC Montlegia
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Philippe Desfontaines, Medical Degree (M.D.)
Contact
philippe.desfontaines@chc.be
00 32 4 355 40 30
Sarah Miceli, Master in Biomedical Sciences
Contact
sarah.miceli02@chc.be
00 4 93 27 28 63

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion